Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).

2023-509776-41-00 Protocol IOR-BMS-IST-002 Human pharmacology (Phase I) - Other Ended

Start 30 Jun 2021 · End 4 May 2026 · Status Ended · 1 EU/EEA countries · 4 sites · Protocol IOR-BMS-IST-002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 48
Countries 1
Sites 4

Non-small cell lung cancer (NSCLC)

Key facts

Sponsor
Instituto Oncologico Dr. Rosell S.L.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
30 Jun 2021 → 4 May 2026
Decision date (initial)
2024-07-23
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-509776-41-00
EudraCT number
2020-005151-20
ClinicalTrials.gov
NCT04772235

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Non-small cell lung cancer (NSCLC)

VersionLevelCodeTermSystem organ class
21.1 PT 10059515 Non-small cell lung cancer metastatic 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Instituto Oncologico Dr. Rosell S.L.

Sponsor organisation
Instituto Oncologico Dr. Rosell S.L.
Address
Calle De Sabino Arana Num. 5
City
Barcelona
Postcode
08028
Country
Spain

Scientific contact point

Organisation
Instituto Oncologico Dr. Rosell S.L.
Contact name
A person designed by the Sponsor

Public contact point

Organisation
Instituto Oncologico Dr. Rosell S.L.
Contact name
A person designed by the Sponsor

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 48 4
Rest of world 0

Investigational sites

Spain

4 sites · Ended
University Hospital Son Espases
Oncology, Carretera Valldemossa 79, 07120, Palma
Hospital Universitari Dexeus Grupo Quironsalud
Oncology, Calle De Sabino Arana 5-19, 08028, Barcelona
Hospital Universitario Regional De Malaga
Oncology, Avenida De Carlos De Haya Sn, 29010, Malaga
Hospital General Universitario Gregorio Maranon
Oncology, Calle Del Doctor Esquerdo 46, 28007, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2021-06-30 2026-05-04 2022-02-11 2025-01-31

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-17 Spain Acceptable with conditions
2024-07-23
2024-07-23